Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder

Eric Chung, Dominic Lee, Johan Gani, Michael Gillman, Christopher Maher, Janelle Brennan, Lydia Johns Putra, Laura Ahmad and Lewis LW Chan
Med J Aust 2018; 208 (1): . || doi: 10.5694/mja16.01097
Published online: 15 January 2018


Introduction: Overactive bladder (OAB) is a highly prevalent medical condition that has an adverse impact on various health-related quality-of-life domains, including a significant psychosocial and financial burden. This position statement, formulated by members of the Urological Society of Australia and New Zealand and the UroGynaecological Society of Australasia, summarises the current recommendations for clinical diagnosis and treatment strategies in patients with non-neurogenic OAB, and guides clinicians in the decision-making process for managing the condition using evidence-based medicine.

Main recommendations:

  • Diagnosis and initial management should be based on thorough clinical history, examination and basic investigations to exclude underlying treatable causes such as urinary tract infection and urological malignancy.
  • Initial treatment strategies for OAB involve conservative management with behavioural modification and bladder retraining.
  • Second-line management involves medical therapy using anticholinergic or β3 agonist drugs provided there is adequate assessment of bladder emptying.
  • If medical therapy is unsuccessful, further investigations with urodynamic studies and cystourethroscopy are recommended to guide further treatment.
  • Intravesical botulinum toxin and sacral neuromodulation should be considered in medical refractory OAB.

Changes in management as a result of this statement:

  • OAB is a constellation of urinary symptoms and is a chronic condition with a low likelihood of cure; managing patient expectations is essential because OAB is challenging to treat.
  • At present, the exact pathogenesis of OAB remains unclear and it is likely that there are multiple factors involved in this disease complex.
  • Current medical treatment remains far from ideal, although minimally invasive surgery can be effective.
  • Further research into the pathophysiology of this common condition will hopefully guide future developments in disease management.

  • 1 Princess Alexandra Hospital, Brisbane, QLD
  • 2 St George Hospital, Sydney, NSW
  • 3 Austin and Repatriation Hospital, Melbourne, VIC
  • 4 Pelvic Medicine Centre, St Andrews War Memorial Hospital, Brisbane, QLD
  • 5 Royal Brisbane and Women's Hospital, Brisbane, QLD
  • 6 Bendigo Health, Bendigo, VIC
  • 7 Ballarat Urology, Ballarat, VIC
  • 8 Ballarat Health Services, Ballarat, VIC
  • 9 Aged Health Network, NSW Agency for Clinical Innovation, Sydney, NSW
  • 10 Concord Repatriation General Hospital, Sydney, NSW


Competing interests:

No relevant disclosures.

  • 1. Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178.
  • 2. Lee UJ, Scott VC, Rashid R, et al. Defining and managing overactive bladder: disagreement among the experts. Urology 2013; 81: 257-262.
  • 3. Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc 2011; 59: 1465-1470.
  • 4. Coyne KS, Sexton CC, Thompson C, et al. The impact of OAB on sexual health in men and women: result from EpiLUTS. J Sex Med 2011; 8: 1603-1615.
  • 5. Brading AF. A myogenic basis for the overactive bladder. Urology 1997; 50(6A suppl): 57-67.
  • 6. de Groat WC. A neurological basis for the overactive bladder, Urology 1997; 50(6A suppl): 36-52.
  • 7. Milson I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int 2001; 87: 760-766.
  • 8. Wang CC, Liao CH, Kuo HC. Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder. Urol Sci 2015; 26: 7-16.
  • 9. Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011; 77: 1081-1087.
  • 10. Lukacz ES, Sampselle C, Gray M, et al. A healthy bladder: a consensus statement. Int J Clin Pract 2011; 65: 1026-1036.
  • 11. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015; 193: 1572-1580.
  • 12. Gormley EA1, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012 Dec; 188(6 Suppl): 2455-2463.
  • 13. Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015; 67: 1099-1109.
  • 14. Tse V, King J, Dowling C, et al. Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non-neurogenic overactive bladder. BJU Int 2016; 117: 34-47.
  • 15. Moore K, Dumoulin C, Bradley C, et al. Adult conservative management. Abrams P, Cordozo L, Koury S, et al, editors. Paris: Health Publications; 2013; p 1101-1226.
  • 16. Gleason JL, Richter HE, Redden DT, et al. Caffeine and urinary incontinence in US women. Int Urogynecol J 2013; 24: 295-302.
  • 17. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev 2012; 12: CD003193.
  • 18. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004; 56: 581-631.
  • 19. Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012; (1): CD005429.
  • 20. Rosa GM, Ferrera S, Nitti VW, et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol 2016; 69: 311-323.
  • 21. Bragg R, Hebel D, Vouri SM, Pitlick JM. Mirabegron: a Beta-3 agonist for overactive bladder. Consult Pharm 2014; 29: 823-837.
  • 22. Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014; 33: 17-30.
  • 23. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 2015; 67: 577-588.
  • 24. Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011; (12): CD005493.
  • 25. Cui Y, Zhou X, Zong H, et al. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis. Neurourol Urodyn 2015; 34: 413-419.
  • 26. Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicentre study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn 2015; 34: 224-230.
  • 27. Van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007; 178: 2029-2034.
  • 28. Peeters K, Sahai A, De Ridder D, Van Der Aa F. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int 2014; 113: 789-794.
  • 29. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183: 1438-1443.
  • 30. Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int 2012; 109: 1280-1293.
  • 31. Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004; 172(4 Pt 2): 1651-1652.
  • 32. Farnham SB, Cookson MS. Surgical complications of urinary diversion. World J Urol 2004; 22: 157-167.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.